Octave Bioscience
Octave Bioscience, Inc. is a leading precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, starting with multiple sclerosis. Octave’s comprehensive solution provides objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes. The company’s flagship product, the Octave Multiple Sclerosis Disease Activity (MSDA) Test, is the first clinically and analytically validated blood-based biomarker test that enables physicians to quantitatively measure MS disease activity, allowing for more informed treatment decisions and personalized disease management over time.
Content by Octave Bioscience
|2 min read
Nationwide Access to New Multi-Analyte Laboratory Test for Multiple Sclerosis
Collaboration brings new hope for patients with multiple sclerosis through expanded access to a clinically validated multi-analyte blood test
|3 min read
Clinically Validated Multiple Sclerosis Multi-Analyte Test Is Now Available in All 50 States
Prior to the MSDA Test, disease management in MS relied primarily on clinical assessments and MRIPage 1 of 1
